Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it has dosed the first patient in its Phase I clinical trial evaluating T...

The ATTEST trial is using a pioneering virus technology to infect cancer cells.

The ATTEST trial is using a pioneering virus technology to infect cancer cells.

JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles.

Virotherapies can deliver anti-cancer therapeutics directly to tumors. Bayliss and colleagues develop a precision virotherapy expressing bispecific immunotherapies from tumor cells resulting in immune...

JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles.

Virotherapies can deliver anti-cancer therapeutics directly to tumours. Bayliss and colleagues develop a precision virotherapy expressing bispecific immunotherapies from tumour cells resulting in immune cell activation and tumour cell killing. Combination cancer therapy has potential to enhance regression of solid tumours in a targeted manner improving on current approaches.